Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333687 | 0.80 | PDE4B (0.48) | PDE4BHRH3OPRM1HRH1 | |
| SCHEMBL6261972 | 0.76 | HRH3 (0.47) | HRH3HRH1FAAH | |
| SCHEMBL3089908 | 0.74 | PDE4B (0.48) | PDE4BHRH3OPRM1HRH1 | |
| SCHEMBL6268381 | 0.71 | HRH3 (0.48) | HRH3HRH1 | |
| SCHEMBL3089905 | 0.70 | HRH3 (0.65) | HRH3HRH1 | |
| SCHEMBL3653092 | 0.66 | HRH3 (0.52) | PDE4BHRH3 | |
| SCHEMBL4363971 | 0.66 | SLC8A1 (0.56) | — | |
| SCHEMBL8306759 | 0.66 | PDE4B (0.52) | PDE4BOPRM1 | |
| SCHEMBL4366489 | 0.65 | SLC8A1 (0.48) | PDE4B | |
| SCHEMBL3334368 | 0.65 | HRH3 (0.51) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | PDE4B 1098/4885HRH3 450/4885OPRM1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.